distribution of stage, year of diagnosis, and risk category in the treatment groups. Table 1. Patient Characteristics Some deviation from protocol-defined treatment was noted in the treatment groups ( supplemental eTable 1 ). In the chemo-PRT group, 3D
Search Results
Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl
George L. Jackson, Leah L. Zullig, S. Yousuf Zafar, Adam A. Powell, Diana L. Ordin, Ziad F. Gellad, David Abbott, James M. Schlosser, Janis Hersh, and Dawn Provenzale
accredited by the American College of Surgeons Commission on Cancer in 2005; an additional 8 facilities [30%] were in the process of applying for accreditation). 21 Characteristics of the 27 facilities using CCQMS reports are detailed in Table 3
Jenna F. Borkenhagen, Daniel Eastwood, Deepak Kilari, William A. See, Jonathan D. Van Wickle, Colleen A. Lawton, and William A. Hall
subclassification ( P <.001). This was a generally healthy cohort, with a CDCI score of 0 in 88% of men, indicating no comorbid conditions recorded ( P =.415). Table 2. Baseline Patient Characteristics Baseline tumor characteristics across cT2 subclassifications
Ang Li, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman, and Kristen M. Sanfilippo
of the Declaration of Helsinki. Use of the VHA database was approved by the St. Louis Veterans Affairs Medical Center IRB. Results Cohort Descriptions Baseline patient characteristics for the derivation (SEER-Medicare) and external validation (VHA
Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh
noncardia primaries. Demographic and clinical characteristics stratified by type of preoperative treatment are summarized in Table 1 . Among patients treated with preoperative chemotherapy, 43.8% of patients received adjuvant therapy (among whom 67
Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Man Ho Hui, Xuejin Liu, Teddy Tai Loy Lee, Kyle Hui, Jeffrey Shi Kai Chan, Abraham Ka Chung Wai, Wing Tak Wong, Tong Liu, Kenrick Ng, Sharen Lee, Edward Christopher Dee, Qingpeng Zhang, and Gary Tse
users. HbA1c (expressed as a percentage) was similar in both metformin and sulfonylurea users (mean [SD], 7.45 [1.47] vs 7.45 [1.42], respectively; SMD, <0.01). Baseline and clinical characteristics of the study cohort before and after propensity score
Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover
validation cohorts. Model performance of the final bootstrapped model was assessed in the training and validation cohorts using receiver operating characteristic (ROC) curves with area under the curve (AUC) statistics; ROC curves compare sensitivity to
Chetna Malhotra, Ling En Koh, Irene Teo, Semra Ozdemir, Isha Chaudhry, and Eric Finkelstein
% answered surveys at 6, 12, 18, and 24 months, respectively. The 134 patients excluded from the analysis were similar to those in our analytic sample (n=466) in terms of age and sex. Table 1 shows patient baseline characteristics. Table 1. Patient
Michael G. Cohen, Andrew D. Althouse, Robert M. Arnold, Douglas White, Edward Chu, Margaret Rosenzweig, Kenneth J. Smith, and Yael Schenker
intervention increased ACP uptake. Baseline characteristics of patients in the CONNECT intervention and standard care arms are presented using frequency and percentages for categorical variables and mean [SD] for continuous variables. Baseline characteristics
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
Clinical Characteristics (N=406) At baseline assessment, most patients (79.3%; n=322/406) did not have neuropathy symptoms (CTCAE grade 0; Table 1 ). By midtreatment (8.9 ± 4.8 weeks from baseline), 62.2% (n=199/320) had CIPN symptoms (CTCAE grade ≥1
